Monoclonal antibody against β - NGF

HA tagged recombinant rabbit monoclonal antibody,Anti-NGF Monoclonal Antibody (Tanezumab)
UA011217

Product Description

Anti NGF Monoclonal Antibody (Tanezumab) is a highly specific and affinity humanized monoclonal antibody that targets nerve growth factor (NGF). This product is produced using a mammalian cell expression system and has excellent inter batch consistency and stability, making it suitable for pain research and related biopharmaceutical development.

Product Features

• Antibody typeHumanized IgG1 monoclonal antibody

• Target specificitySpecific binding of human/mouse/rat NGF

• affinityKd<1 nM (SPR assay)

• expression systemCHO cell expression

• purity：>95%（SEC-HPLC）

• endotoxin：<1 EU/mg

• preparationPBS buffer (pH 7.4)

• Storage conditionsLong term storage at -20 ℃ to -80 ℃ to avoid repeated freeze-thaw cycles

application field

• Research on Pain MechanismsResearch on Chronic Pain and Osteoarthritis Pain Models

• Antibody drug developmentResearch and development of NGF targeted therapeutic drugs

• In vitro testing：ELISA、Western Blot、 Immunoprecipitation and other experiments

• preclinical researchPharmacodynamic and pharmacokinetic evaluation

quality assurance

• Strict quality control: Provide binding activity testing reports for each batch

• Serum free production: no animal derived ingredients throughout the entire process

• Stability data: Accelerated stability testing supports long-term preservation

Usage recommendations

1. The working concentration needs to be optimized according to the experimental system (recommended starting concentration of 1-10 μ g/mL)

2. After thawing, it is recommended to store at 4 ℃ and use within one month

3. Avoid using buffer solutions containing NaN3

Regarding Starter, a domestic antibody expert:
Hangzhou StartechWe aim to provide high-quality products and research and development services for the global life science industry, including antibodies, proteins, reagent kits, and more. Relying on multiple development platforms: recombinant monoclonal antibodies, recombinant mouse monoclonal antibodies, rapid mouse monoclonal antibodies, recombinant protein development platforms (E. coli, CHO, HEK293, InsectCells), it has officially passed the EU 98/79/EC certification ISO9001 certification ISO13485